Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics awarded $2.6 million FDA grant for MT-601 pancreatic cancer study

Neutral Impact 2 of 5 financing Written later

Marker Therapeutics said the FDA awarded it $2.6 million through its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in patients with locally advanced unresectable pancreatic cancer. The company describes the funding as non-dilutive, and it expects clinical initiation of the study in the first quarter of 2027.

Key points

  • FDA award of $2.6 million under the Orphan Products Clinical Trials grants program, announced October 19, 2026
  • Grant will support a Phase 1 study of lead candidate MT-601 in locally advanced unresectable pancreatic cancer
  • FDA received 66 applications and selected six projects for funding in fiscal year 2026
  • Marker expects to begin clinical initiation of the pancreatic cancer study in the first quarter of 2027

The filing

CompanyMarker Therapeutics, Inc. (MRKR)
Form8-K, current report
Filed with the SECOct 19, 2026, 7:12 AM ET
Accession number0001104659-26-116720

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.